Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist
The advent of combination immunotherapy has revolutionized the treatment of metastatic renal cell carcinoma (mRCC), leveraging immune checkpoint inhibitors and tyrosine kinase inhibitors to improve survival outcomes. However, these advancements come with a significant challenge: the management of ad...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-08-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/17562848251358174 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850043696933765120 |
|---|---|
| author | Angelo Del Gaudio Loris Riccardo Lopetuso Valeria Pavese Erica Palesandro Ilaria Campisi Marcello Tucci Franco Scaldaferri |
| author_facet | Angelo Del Gaudio Loris Riccardo Lopetuso Valeria Pavese Erica Palesandro Ilaria Campisi Marcello Tucci Franco Scaldaferri |
| author_sort | Angelo Del Gaudio |
| collection | DOAJ |
| description | The advent of combination immunotherapy has revolutionized the treatment of metastatic renal cell carcinoma (mRCC), leveraging immune checkpoint inhibitors and tyrosine kinase inhibitors to improve survival outcomes. However, these advancements come with a significant challenge: the management of adverse effects, which can impair patients’ quality of life and lead to therapy discontinuation. This review explores the prevalence, mechanisms, and management of gastrointestinal (GI) toxicity associated with immunotherapy combinations for mRCC from the gastroenterologist’s perspective. Diarrhea, colitis, nausea, and vomiting are the most frequently reported adverse events, often necessitating a multidisciplinary approach for timely diagnosis and intervention to mitigate risks and ensure therapeutic continuity. We highlight the management strategies, ranging from symptomatic treatment and dietary modifications to advanced therapies for severe cases, even discussing the emerging approaches for refractory cases. By integrating oncological and gastroenterological expertise, clinicians can optimize outcomes for patients while minimizing GI-related complications. |
| format | Article |
| id | doaj-art-2d45b2f75ac14f879c20134b4212de7e |
| institution | DOAJ |
| issn | 1756-2848 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj-art-2d45b2f75ac14f879c20134b4212de7e2025-08-20T02:55:10ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482025-08-011810.1177/17562848251358174Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologistAngelo Del GaudioLoris Riccardo LopetusoValeria PaveseErica PalesandroIlaria CampisiMarcello TucciFranco ScaldaferriThe advent of combination immunotherapy has revolutionized the treatment of metastatic renal cell carcinoma (mRCC), leveraging immune checkpoint inhibitors and tyrosine kinase inhibitors to improve survival outcomes. However, these advancements come with a significant challenge: the management of adverse effects, which can impair patients’ quality of life and lead to therapy discontinuation. This review explores the prevalence, mechanisms, and management of gastrointestinal (GI) toxicity associated with immunotherapy combinations for mRCC from the gastroenterologist’s perspective. Diarrhea, colitis, nausea, and vomiting are the most frequently reported adverse events, often necessitating a multidisciplinary approach for timely diagnosis and intervention to mitigate risks and ensure therapeutic continuity. We highlight the management strategies, ranging from symptomatic treatment and dietary modifications to advanced therapies for severe cases, even discussing the emerging approaches for refractory cases. By integrating oncological and gastroenterological expertise, clinicians can optimize outcomes for patients while minimizing GI-related complications.https://doi.org/10.1177/17562848251358174 |
| spellingShingle | Angelo Del Gaudio Loris Riccardo Lopetuso Valeria Pavese Erica Palesandro Ilaria Campisi Marcello Tucci Franco Scaldaferri Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist Therapeutic Advances in Gastroenterology |
| title | Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist |
| title_full | Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist |
| title_fullStr | Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist |
| title_full_unstemmed | Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist |
| title_short | Management of gastrointestinal adverse effects in immune-based combination therapy for advanced renal carcinoma: when the oncologist meets the gastroenterologist |
| title_sort | management of gastrointestinal adverse effects in immune based combination therapy for advanced renal carcinoma when the oncologist meets the gastroenterologist |
| url | https://doi.org/10.1177/17562848251358174 |
| work_keys_str_mv | AT angelodelgaudio managementofgastrointestinaladverseeffectsinimmunebasedcombinationtherapyforadvancedrenalcarcinomawhentheoncologistmeetsthegastroenterologist AT lorisriccardolopetuso managementofgastrointestinaladverseeffectsinimmunebasedcombinationtherapyforadvancedrenalcarcinomawhentheoncologistmeetsthegastroenterologist AT valeriapavese managementofgastrointestinaladverseeffectsinimmunebasedcombinationtherapyforadvancedrenalcarcinomawhentheoncologistmeetsthegastroenterologist AT ericapalesandro managementofgastrointestinaladverseeffectsinimmunebasedcombinationtherapyforadvancedrenalcarcinomawhentheoncologistmeetsthegastroenterologist AT ilariacampisi managementofgastrointestinaladverseeffectsinimmunebasedcombinationtherapyforadvancedrenalcarcinomawhentheoncologistmeetsthegastroenterologist AT marcellotucci managementofgastrointestinaladverseeffectsinimmunebasedcombinationtherapyforadvancedrenalcarcinomawhentheoncologistmeetsthegastroenterologist AT francoscaldaferri managementofgastrointestinaladverseeffectsinimmunebasedcombinationtherapyforadvancedrenalcarcinomawhentheoncologistmeetsthegastroenterologist |